

Matsumoto et al.
U.S.S.N. 09/868,885
Amendment
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-12. (Cancelled).

13. (New) A method of regulating oxytocin secretion comprising administering to a patient in need of oxytocin secretion regulation, an effective amount of an isolated and purified oxytocin secretion regulator, comprising a ligand peptide, or salt thereof, for a G protein-coupled receptor protein, phGR3, wherein the ligand peptide, or salt thereof, for a G protein-coupled receptor protein is a polypeptide, or an amide or an ester or a salt thereof, containing an amino acid sequence that has at least 90% homology to the amino acid sequence represented by SEQ ID NO: 44.

14. (New) The method of claim 13, wherein the ligand peptide has an amino acid sequence that has at least 95 % identity to the amino acid sequence represented by SEQ ID NO: 44.

15. (New) The method of claim 13, wherein the amino acid sequence represented by SEQ ID NO: 44 is selected from the group consisting of SEQ ID NO: 3, 18, and 32.

16. (New) The method of claim 13, wherein the isolated and purified oxytocin secretion regulator is an oxytocin secretion promoter.